Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD Disclosure.
On October 6, 2018, Blueprint Medicines Corporation issued a press release announcing the presentation of updated data for RET-altered medullary thyroid cancer (“MTC”) patients and papillary thyroid cancer patients from its ongoing Phase 1 ARROW clinical trial evaluating BLU-667 for the treatment of RET-altered non-small cell lung cancer, MTC and other advanced solid tumors. The data were presented on Saturday, October 6, 2018 in an oral presentation at the 88thAnnual Meeting of the American Thyroid Association (the “ATA Annual Meeting”)in Washington, D.C.A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the presentation at the ATA Annual Meeting is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.